| VascuLAST™ coatings are |
 |
| Versatile |
|
| VascuLAST™ can be the host matrix for a variety of anti-restenosis compounds. Bioactive compounds that act by inhibiting angiogenesis, inflammation, smooth muscle cell proliferation, or the clotting cascade can be incorporated. |
|
| Uniform |
|
| VascuLAST™ is applied by a process that is easily scaled up and can be adapted to any stent design. The coating is uniform and does not bridge over any part of the stent. |
|
| Customized |
|
| VascuLAST™ has been shown to be effective in the reduction of restenosis with certain stent designs and bioactive compounds. It can be customized to include compounds prescribed by a device manufacturer or can be used as part of a coating offered by a pharmaceutical manufacturer. AST works with customers closely through the development process to ensure that the coating meets the design requirements of any kind of customer. |
|
| Flexible and tenacious |
|
| VascuLAST™ coatings strongly adhere to substrates even when the devices are fully expanded with no flaking or delamination. |
|
| Controllable |
|
| VascuLAST™ coatings can be enhanced with a patented AST treatment that controls and prolongs the release of agents into surrounding tissue. |
|
|
|
|
|
| How does VascuLAST™ work? |
|
 |
|
| Another new coating in the BioLAST family, VascuLAST™ is a surface treatment used to prevent the re-narrowing of vessels after medical intervention. While this usually happens during angioplasty procedures, it may also occur elsewhere. AST-sponsored animal trials have demonstrated the successful use of VascuLAST™ to incorporate anti-restenosis agents into implantable devices. |
|
